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ABSTRACT 
Background: 
High inflammatory bowel disease (IBD) rates have been reported in Australasia, but no 
state-wide studies have yet been performed. 
This article is protected by copyright. All rights reserved.
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Aims: 
This study estimates the one-year incidence and point prevalence of IBD in the state of 
Tasmania, Australia. It also reports clinical outcomes after twelve months of diagnosis 
in an incident cohort. 
 
Methods  
A prospective, population-based study was performed collecting prevalent and 
incident state-wide cases from 1st June 2013 to 31st May 2014. Case data were 
identified from specialist doctors, pathology databases and hospital records. Age-
standardised rates (ASRs) were calculated based on World Health Organization 2000 
standard population characteristics. Incident cases were followed up twelve months 
after diagnosis. 
 
Results 
There were 1719 prevalent cases: ASRs for IBD, Crohn’s disease (CD), ulcerative colitis 
(UC) and inflammatory bowel disease unclassified (IBDU) prevalence were 303.9, 
165.5, 131.4 and 6.9 per 100,000 respectively. Prevalent CD cases were younger, with 
greater immunomodulator/biologic use and bowel resections. There were 149 incident 
cases: ASRs for IBD, CD, UC and IBDU incidence were 29.5, 15.4, 12.4, and 1.7 per 
100,000 respectively. Incident CD cases were more likely than UC or IBDU to require 
escalation of medical therapy, hospitalisation, and bowel resection especially among 
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those with penetrating or stricturing disease. They had longer duration of symptoms 
prior to diagnosis. 
 
Conclusions 
IBD prevalence and incidence rates are high in Tasmania, comparable to data from 
other Australasian studies and those from Northern Europe and America. Poorer 
twelve month clinical outcomes occurred in complicated CD, with greater use of 
healthcare resources. 
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INTRODUCTION 
Inflammatory bowel disease (IBD), a significant global health burden1-3, includes 
distinct phenotypes of Crohn’s disease (CD), ulcerative colitis (UC) and inflammatory 
bowel disease unclassified (IBDU)4, 5. Few studies have explored the epidemiology of 
IBD in Australasia. Gearry et al reported on IBD epidemiology in the Canterbury region 
of New Zealand in 20066 and 20147. Wilson et al8, Studd et al9 and Niewiadomski et al10  
conducted similar research in the Barwon region of Victoria, Australia between 2010 
and 2016. These studies reports epidemiological rates similar to Northern Europe and 
America, which are among the highest in the world. 
 
This study aimed to calculate the population-based one-year incidence of IBD from 1st 
June 2013 to 31st May 2014, and point prevalence of IBD on 31st May 2014, in 
Tasmania, an island state off the south coast of Australia. We hypothesised that the 
IBD burden in Tasmania may be higher than in Barwon due to greater distance from 
the equator, which has been suggested as a risk factor in Northern hemisphere 
studies2, 11; as well as genetic enrichment for IBD susceptibility genes12 in a 
geographically enclosed population through a founder effect13, 14. We also aimed to 
describe phenotypes and disease course in the first twelve months after diagnosis, and 
determine predictors of outcomes such as escalation of medical therapy or bowel 
resection. 
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MATERIALS AND METHODS 
Population 
A population-based, epidemiological prospective cohort study was performed in 
Tasmania during the study period from 1st June 2013 to 31st May 2014, with incident 
cases during this period also followed up twelve months after diagnosis. Tasmania has 
a population of 513,100 as per 2013 census results with over 80% of its population of 
Caucasian background15. It lies approximately 200 kilometres further south of the 
equator than Barwon: the latitude of Geelong, the population centre of Barwon, is 
38.14o south; the latitudes of Launceston and Hobart, the two major population 
centres of Tasmania, are 41.43o and 42.88o south. 
 
Case Capture 
Data about IBD cases were obtained using a modification of multiple case-capture 
methodologies used in the Barwon study9. Incident and prevalent cases were obtained 
from two sources: 30 specialists treating IBD during the one-year study period, 
including gastroenterologists, paediatricians and surgeons; and state-wide pathology 
databases. Case data were submitted to the primary author (RB) by specialists after 
relevant consultations. Specialists were also reminded every 2 months to contribute 
cases. There were no demographic exclusion criteria. 
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Histopathology databases were searched to identify additional IBD cases at the end of 
the study period. Searches were conducted using the terms “IBD”, “ulcerative colitis”, 
“Crohn’s disease”, “colitis” and “ulcerative proctitis”, from 1st Jan 1986 up to the end 
of the study period. Neither self-referrals from the broader community nor referrals 
from primary care practitioners were sought. Hospital International Classification of 
Disease (ICD) discharge codes were not analysed as a source of eligible cases. It was 
felt that these methods of case recruitment had potentially poor specificity. 
 
Case confirmation 
Among patients submitted by specialists, incident cases were defined as those newly 
diagnosed during the study period; and included only if independently confirmed to be 
a true case by a co-author (CS) using the Copenhagen diagnostic criteria, a composite 
of clinical, endoscopic, histological and radiological findings16, 17. Prevalent cases 
included were those defined as having IBD, diagnosed at any time, according to a 
specialist’s professional opinion.  
 
Among cases identified through histopathology databases, those with acute or self-
limited infectious colitis (with no signs of chronicity on histology and corresponding 
pathogens found on microbiological testing) and microscopic colitis were excluded, as 
were those previously submitted by specialists. Among the remaining cases, those 
newly diagnosed with IBD during the study period and fulfilling Copenhagen criteria 
were included as additional incident cases. Cases were included as additional prevalent 
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cases if they had recently engaged in health care, either through outpatient 
consultation with IBD specialists or attendance to hospital, during the 18 month period 
prior to 31st May 2014. This cut-off was implemented to maximise the likelihood of 
them living in Tasmania at this date.   
 
Epidemiological data collection 
Epidemiological endpoints were IBD, CD, UC and IBDU point prevalence rates at 31st 
May 2014 and incidence rates between 1st June 2013 and 31st May 2014. Crude 
prevalence and incidence rates of IBD, with sub-analyses for CD, UC and IBDU, were 
calculated using the state population as the denominator. Rates were expressed as 
cases per 100,000 population. Age-standardised rates (ASRs) were calculated using the 
direct method, based on World Health Organization (WHO) year 2000 standard 
population characteristics18. Rates were presented with 95% confidence intervals (CI) 
based on an assumed Poisson distribution.   
 
Clinical data collection  
Case data were collected from treating specialists and/or hospital medical records. 
This included patient demographics, smoking status (current, former or never), disease 
duration and phenotype, bowel resections and use of immunomodulators and 
biologics. For incident cases, additional data included endoscopy, histology and 
radiology investigations, Montreal criteria sub-classifications19, hospitalisation, surgery 
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and/or pharmacotherapy during the first month after diagnosis as well as at twelve 
months after diagnosis. 
 
For UC, disease distribution was divided into proctitis (E1), left-sided colitis up to the 
splenic flexure (E2) and extensive colitis (E3). For CD, distribution was divided into ileal 
(L1), colonic (L2) and ileocolonic (L3). For CD, behaviour was divided into non- 
stricturing/ non-penetrating (inflammatory) (B1), stricturing (B2) and penetrating (B3). 
B2 necessitated obstructive symptoms or radiological demonstration of proximal 
bowel dilatation. B3 required intra-abdominal fistula or abscesses, but excluded 
isolated perianal fistulae.  
 
Data analysis 
Statistical analysis was conducted using R Software, Version 3.0.1; (R Foundation for 
Statistical Computing, Vienna, Austria).  Categorical data were analysed with Pearson 
χ2 tests. Non-parametric continuous data were summarised as medians and 
interquartile ranges (IQR) and group differences were analysed by Mann-Whitney U-
testing and Kruskal-Wallis analysis of variance by ranks. P-values <0.05 were 
considered statistically significant.  
Ethics 
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This study was approved by the Tasmanian Human Research Ethics Committee 
(approval number: H0013057). Each case was allocated a study code and patient 
information was de-identified. Direct contact with patients was not made. 
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RESULTS 
Prevalent cohort 
On 31st May 2014 there were 1719 prevalent IBD cases, 792 (41.6%) males and 927 
(58.4%) females, including 874 (50.8%) CD, 803 (46.7%) UC and 42 (2.4%) IBDU. Crude 
point prevalence per 100,000 of overall IBD, CD, UC and IBDU was 335.0 (95% CI: 
319.2, 350.9), 170.3 (159.0, 181.6), 156.5 (145.7, 167.3) and 8.2 (5.7, 10.7) 
respectively. The ASR for overall IBD prevalence was 303.9 per 100,000 (CI: 288.6, 
319.2); the ASRs were 165.5 (154.0, 177.1) for CD; 131.4 (121.7, 141.1) for UC; and 6.9 
(4.7, 9.2) for IBDU. Median duration of disease was 8 years (IQR= 10) and median age 
at diagnosis was 36 years (IQR=28). A peak in IBD prevalence occurred among those in 
the sixth decade of life (Figure 1).  
 
Those with CD, compared to both UC and IBDU, were both younger and diagnosed at 
an earlier age; more likely to be using immunomodulators and biologics at time of 
referral for study inclusion; and more likely to have had bowel resections. Compared to 
UC, those with CD were more likely female and have a history of smoking. Further 
details are provided in Table 1.  
 
Incident cohort 
There were 149 incident cases during the study period from 1st June 2013 to 31st May 
2014, 84 (56.4%) males and 65 (43.6%) females, including 74 (49.6%) CD, 63 (42.2%) 
UC and 12 (8.1%) IBDU. Crude incidence per 100,000 of overall IBD, CD, UC and IBDU 
was 29.0 (CI: 24.4, 33.7), 14.4 (11.1, 17.7), 12.3 (9.2, 15.3) and 2.4 (1.0, 3.7) 
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respectively. The ASR for overall IBD incidence per 100,000 was 29.5 (CI: 24.5, 34.5). 
The ASRs were 15.4 (11.7, 19.1) for CD; 12.4 (9.2, 15.6) for UC; and 1.7 (0.7, 2.8) for 
IBDU. Median age at diagnosis was 41 years (IQR= 34). A peak in IBD incidence 
occurred among those in the third decade of life. A second peak of IBD in the sixth 
decade of life was largely attributable to UC (Figure 2).  Median length of symptoms 
prior to diagnosis was 13 weeks (IQR= 28, range= 1-748), 
 
There was a predominance of males in UC and females in IBDU.  CD cases were 
younger than UC at diagnosis with a trend toward significance. IBDU cases were 
significantly older than CD and UC cases. More CD cases had a positive IBD family 
history than UC. Current smoking rates were higher in CD than in UC: however there 
were no significant differences in former smoking rates. CD cases also reported longer 
length of symptoms prior to diagnosis. Further details are provided in Table 2.  
 
Incident diagnosis and classifications 
Among UC cases, colonic disease extent was quite evenly split between E1 (n= 20, 
31.7%), E2 (n=20, 31.7%) and E3 (n=23 36.5%). Among CD cases, locations were quite 
evenly split between L1 (n=21, 28.3%), L2 (n=27, 36.5%) and L3 (n=25, 33.8%). CD 
behaviour was predominantly B1 (n=60, 81.1%). Eleven cases (14.9%) had B2 disease 
and 3 (4.1%) had B3 disease.  
 
Disease progress 
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Data for follow-up was provided for 141 of 149 cases (94.6%) at the twelfth month 
after diagnosis. Median number of outpatient visits (clinic or endoscopy) per case was 
6 (IQR 4, range 1-19). 45 cases (30.2%) had at least 1 IBD-related hospitalisation. 
Among those hospitalised, median total length of inpatient time was 8 days (IQR 10, 
range 1-55). Fifteen (10%) cases had bowel resections, five (4 CD, 1 UC) having total 
colectomies for severe disease. Two cases had resections for colonic lesions (1 CD for 
caecal adenocarcinoma, 1 UC for large caecal adenoma). 
 
CD cases were more likely than UC or IBDU to be hospitalised within the first twelve 
months, however there was no significant difference between median total time of 
inpatient stay between IBD phenotypes. CD cases had longer length of symptoms prior 
to diagnosis, more bowel resections, and more combined outpatient and endoscopy 
sessions. Table 3 provides further details. 
 
With B2 and B3 CD combined as a subgroup of ‘complicated disease’, this subgroup 
had significantly higher rates of bowel resection (66.7%) than B1 CD (8.1%, p < 0.001). 
Those with L1 CD had longer median length of symptoms (in weeks) pre-diagnosis (52, 
IQR 359) than those with L2 (13, IQR 20, p=0.003), L3 (2, IQR 24, p=0.027) or a 
combined subgroup of L2 and L3 CD (18, IQR 24, p=0.213). Those with E3 UC (30.4% vs 
0%, p=0.023), or E2 UC (25% vs 0%, p=0.056), were more likely to be hospitalised than 
those with E1 UC. 
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Predictors of bowel resection in CD 
Univariate logistic regression was performed analysing predictors of bowel resection in 
CD (excluding carcinoma). Predictive factors identified included older age (OR 1.03, CI: 
1.01-1.07, p<0.01), current or former smoking (OR 5.5, CI: 1.37-22.1, p= 0.016) and 
B2/B3 behaviour (OR 13.1, CI: 3.15-54.2, p<0.01). Use of steroids in the first month was 
protective against resection (OR 0.25, CI: 0.074-0.885, p= 0.032). However gender, CD 
location, length of symptoms pre-diagnosis and use of immunomodulators or biologics 
were not predictive. Predictive factors were entered into a stepwise multivariate 
logistic regression model. Only B2/B3 behaviour remained independently predictive of 
resection (OR 7.16, CI: 1.51-33.92, p=0.013). 
 
Medications 
Overall, at both one month and twelve months post-diagnosis, there was higher use of 
systemic steroids, immunomodulators and biologics in CD compared to UC, and less 
use of aminosalicylates. Further details are provided in Table 4. 
 
Medications were classified into five levels of increasing potency: no treatment, 
aminosalicylates +/- topical steroids, systemic steroids, immunomodulators, and 
biologics. Using this classification, 47 cases had an escalation in their most potent level 
of therapy between first month and twelfth month after diagnosis including 37 with CD 
(50%), 8 with UC (12.7%) and 2 with IBDU (16.7%). 
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Univariate logistic regression was performed analysing predictors of escalation. 
Predictive factors identified included younger age (OR 0.97, CI: 0.96, 0.99, p= 0.015), 
having CD (OR 6.17, CI: 2.56-14.83, p= <0.001) and longer length of symptoms (in 
weeks) prior to diagnosis (OR 1.006, CI: 1.001-1.01, p= 0.011). Gender and smoking 
were not predictive. Predictive factors were entered into a stepwise multivariate 
logistic regression model. Only CD (OR 5.01, CI: 2.02-12.4, p = 0.001) and longer length 
of symptoms (OR 1.005, CI: 1.001-1009, p= 0.21) remained independently predictive of 
escalation.  
 
DISCUSSION 
Prevalent cohort 
Prevalence rates of IBD in our study were comparable with previous Australasian data. 
Data from Barwon in 2010-2011 report similar crude twelve-month period prevalence 
rates for IBD, CD, UC and IBDU of 344.6, 197.3, 136 and 8.5 per 100,000 respectively9. 
In Canterbury, crude point prevalence rates on 1st June 2005 were 308.2, 155.2, 145.0 
and 8.0 per 100,000 respectively6. The 95% CIs for crude IBD prevalence rates per 
100,000 in Barwon (309.6, 383.4), Canterbury (292.2, 324.3) and our study (319.2, 
350.9) overlapped, suggesting similar prevalence across the Australasian region. These 
rates are comparable to those reported from Scandinavia and Canada 20-23, with similar 
peaks in the sixth decade of life 21.  
Incident cohort 
 
This article is protected by copyright. All rights reserved.
A
cc
ep
te
d 
A
rti
cl
e
Crude IBD, CD, UC and IBDU one-year incidence rates in our study were also 
comparable with previous Australasian data. Data from Barwon in 2010-2011 report an 
incidence of 24.2, 14.7, 7.5 and 2.0 per 100,000 respectively9. The 95% CIs for crude 
IBD incidence rates per 100,000 in the most recent Barwon data (18.9, 30.5) and our 
study (24.4, 33.7) overlapped, suggesting no significant difference in incidence across 
Australian regions. In Canterbury, New Zealand in 20046, crude IBD, CD and UC one-
year incidence rates were of 25.2, 16.5 and 7.6 per 100,000 respectively. However, by 
2014, these rates had significantly increased to 39.5, 26.4 and 12.6 per 100,000 
respectively7, with the IBD incidence rate (CI: 34.4, 45.3) significantly higher than both 
Australian studies. Potential explanations included increased colonoscopy uptake and 
increased health-seeking among the population. Australasian IBD incidence rates are 
comparable to those in Scandinavia and Canada which are among the highest in the 
world24, 25, with similar peaks in the third decade of life22 . They are also higher than 
rates of between 1-2 per 100,000 in other areas of the Asia-Pacific region1,26; genetic, 
dietary and climate-related factors may explain these differences. 
 
Studies from Europe27-29 and North America11, 30 suggest IBD incidence increases with 
latitudes further from the equator. However among Australasian data from Barwon, 
Tasmania, and the more southerly Canterbury region of New Zealand (latitude of the 
population centre of Christchurch 43.52o south), latitude differences between the 
three regions may not be large enough to exert consistent effects on IBD 
epidemiology. Further studies from tropical northern Australia are awaited. 
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Though more incident cases of UC were male in our study, a systemic review of the 
international literature suggests no sex-specific trends in IBD incidence31. Our finding 
that CD is diagnosed at an earlier age than UC (31.5 years vs 42 years) does reflect 
international findings32. Our observed ‘second peak’ of UC in the 6th decade of life has 
also been described in other studies33. The proportions of incident disease location (L1-
L3, E1-E3) in our study were similar to other Australasian studies7,9, and CD behaviour 
was predominantly B1, reflecting both Australian and international literature34.  
 
Consistent with other studies, we found a significantly longer length of preceding 
symptoms in CD compared to UC and IBDU, driven by a longer length of symptoms in 
L1 compared to L2 or L3 disease. A lack of frank PR bleeding or diarrhoea in such cases 
may increase diagnostic delay35. Those with longer symptoms pre-diagnosis were also 
more likely to require therapeutic escalation, independent of IBD phenotype, perhaps 
due to a greater inflammatory burden of disease at diagnosis. 
 
Medications in first twelve months after diagnosis 
We found significant differences in the medication regimens prescribed between 
different phenotypes of IBD, with CD more likely than UC or IBDU to be treated with 
steroids, immunomodulators, biologics and have therapy escalated between the first 
and twelfth month after diagnosis. In a large 2011 European cohort36, 56% of CD cases 
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had used immunomodulators by the first year of therapy. We report an even higher 
proportion of 74% of CD cases, and similarly use of biologics in 21.6% of CD cases, 
higher than recent cohorts from Barwon (18.1%)10 and Western Europe (19%)36. Of 
note, there were no significant differences in immunomodulator or biologic use 
between different phenotypes of CD or extent of UC. This differs from other studies in 
CD, wherein those with B1 behaviour had lower rates36, 37.  
 
Complications in first twelve months after diagnosis 
CD hospitalisation rates were higher than UC (41.9% vs 19%), consistent with findings 
from the Barwon cohort (28% vs 17%)10 and European studies38. However, unlike other 
studies, we found no association between ileocolonic location or penetrating 
behaviour and hospitalisation rates10. Among those with CD, B2 or B3 behaviour 
independently increased the risk of surgical bowel resection compared to B1 
behaviour, also demonstrated in the Barwon cohort10 and European studies39, 40. 
Conversely, we did not find that other commonly described risk factors such as ileal 
location, younger age at diagnosis or steroids at diagnosis independently associated 
with increased resection rates, perhaps due to low absolute numbers.  
 
Strengths and Limitations 
This is the first Australasian state-wide study of IBD. Strengths include using the whole 
state as the reference population, intensive capture-recapture methodology, and 
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rigorous case definition. However data were not collected about patients’ 
socioeconomic analysis, ethnicity, or geographical proximity to health services; nor 
about laboratory results, medication doses or extra-intestinal manifestations, which 
may be predictors of surgical resection41. Only two discrete data points were chosen at 
one month and twelve months post-diagnosis in the incident cohort. Other studies3 
collected data in shorter intervals and thus described outcome timing in finer detail.  
Patients may have been missed due to investigators recruiting almost exclusively from 
specialists rather than any other medical professionals or hospital discharge codes. 
However the general consensus of specialists involved in recruitment was that that IBD 
patients in Tasmania (even those with stable disease) are likely to have in-state 
specialist review at a minimum frequency of 12 months, rather than be managed 
exclusively in primary care or elsewhere. Furthermore, IBD patients missed by 
specialists (either due to clinic non-attendance during the 12-month study period or 
management elsewhere) were likely to be picked up by the histopathology database 
search and subsequent medical record review. This methodology recruited additional 
patients with histological findings of IBD collected in Tasmania since 1st January 1986, 
strengthening the specificity of the recruitment process. Nonetheless, some IBD 
patients may have had histological diagnosis elsewhere before moving to Tasmania 
and also missed specialist review during the study period. Potential omission of such 
patients is a limitation of this study that may underestimate IBD prevalence.  
 
CONCLUSION: 
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High IBD incidence and prevalence rates in Tasmania are similar to other studies in 
Australasia as well as Northern Europe and America.  CD cases experienced greater 
complications, health resource utilisation, medical therapy escalation and bowel 
resection than other phenotypes. Those with isolated ileal IBD experienced diagnostic 
delay; stricturing and penetrating CD behaviours were independent risk factors for 
bowel resection; and the extent of UC was an independent risk factor for 
hospitalisation.  
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Table 1: Demographic details and disease characteristics of prevalent IBD cases. 
 
CD 
(n=874) 
UC 
(n=803) 
IBDU 
(n=42) 
P value 
(CD vs 
UC) 
P value 
(CD vs 
IBDU) 
P value 
(UC vs 
IBDU) 
Male (%) 42.3 49.8 52.4 0.02 0.60 0.92 
Age, (median, IQR) 
(years) 
45 (26) 54 (24) 51 
(20.75) 
<0.001 0.008 0.94 
Age at diagnosis 
(median, IQR) (years) 
31 (23.7) 40 (25) 46.5 (29) <0.001 <0.001 0.20 
Smoking (current or 
former) (%) 
32 21.4 23.9 <0.001 0.34 0.09 
Immunomodulator 
use (%) 
62.6 24.4 26.1 <0.001 <0.001 0.92 
Biologic use (%) 27.2 4.3 11.9 <0.001 0.04 0.06 
Previous bowel 
resections (%) 
40.7 7.8 7.1 <0.001 <0.001 0.88 
Previous total 
colectomy (%) 
7.3 6.6 4.8 0.7 0.86 0.84 
 
IBD= inflammatory bowel disease. CD= Crohn’s disease. UC= ulcerative colitis. IBDU= 
inflammatory bowel disease-unclassified. IQR= interquartile range. 
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Table 2: Demographic details and disease characteristics of incident IBD cases  
 
CD 
(n=74) 
UC 
(n=63) 
IBDU 
(n=12) 
P value 
(CD vs 
UC) 
P value 
(CD vs 
IBDU) 
P value 
(UC vs 
IBDU) 
Male (%) 54.1 65.1 25 0.41 
 
0.12 0.02 
Age, (median, IQR) 
(years) 
31.5 
(25.5) 
42 (27) 65 (20) 0.06 0.012 0.01 
Smoking (current) (%) 21.6 6.3 8.3 0.01 0.35 0.71 
Smoking (former) (%) 20.1 19 9.3 0.85 0.34 0.62 
Family history of IBD 
(%) 
29.7 9.5 8.3 0.003 0.23 0.68 
Length of symptoms 
pre-diagnosis 
(median, IQR)  
(weeks) 
26 (40) 12  (20) 12 (16) 0.003 0.039 0.95 
 
IBD= inflammatory bowel disease. CD= Crohn’s disease. UC= ulcerative colitis. IBDU= 
inflammatory bowel disease-unclassified. IQR= interquartile range.  
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Table 3: Disease characteristics and clinical progress in incident IBD cohort 
 
 CD 
(n=74) 
UC 
(n=63) 
IBDU 
(n=12) 
P value 
(CD vs 
UC) 
P value 
(CD vs 
IBDU) 
P value 
(UC vs 
IBDU) 
Length of symptoms 
pre-diagnosis 
(median, IQR)  
(weeks) 
26 (40) 12  (20) 12 (16) 0.003 0.039 0.95 
Hospitalized (%) 43.2 17.4 16.7 0.002 0.025 0.67 
Total days of 
inpatient stay 
(median, IQR) 
9 (10) 7 (3.5) 32 (NA) 0.209 0.09 0.05 
Surgery (total) (%) 25.7 3.2 8.3 0.002 0.004 0.72 
Surgery (bowel 
resection) (%) 
18.9 3.2 0 0.004 0.008 0.84 
Outpatient/ 
endoscopy sessions 
(median, IQR) 
7 (5) 4.5 (4) 5 (3.3) 0.001 0.037 0.865 
IBD= inflammatory bowel disease. CD= Crohn’s disease. UC= ulcerative colitis. IBDU= 
inflammatory bowel disease-unclassified. IQR= interquartile range. 
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Table 4: patterns of medication use in incident IBD cohort. 
 
CD 
(n=74) 
UC 
(n=63) 
IBDU 
(n=12) 
P- 
value 
(CD vs 
UC) 
P- value 
(CD vs 
IBDU) 
P 
value= 
(UC vs 
IBDU) 
1st month therapy 
    
Aminosalicylates +/- topical 
steroids(%) 
25.7 84.1 91.7 0.001 0.001 0.81 
Systemic steroids(%) 56.7 31.7 8.3 0.005 0.005 0.19 
Immunomodulators(%) 27 3.2 0 0.0004 0.09 0.73 
Biologics(%) 2.7 0 0 0.5 0.64 N/A 
12th month therapy* 
    
Aminosalicylates  +/- 
topical steroids (%) 
33.7 84.1 100 0.0001 0.0001 0.30 
Systemic steroids(%) 70.2 39.7 16.7 0.0006 0.0012 0.23 
Immunomodulators(%) 75.7 12.7 0 0.001 0.001 0.42 
Biologics(%) 
21.6 0 0 0.001 0.16 N/A 
*This denotes if patients had ever been treated with the listed medications in the first 12 
months.  
IBD= inflammatory bowel disease. CD= Crohn’s disease. UC= ulcerative colitis. IBDU= 
inflammatory bowel disease-unclassified.  
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FIGURE LEGENDS 
Figure 1: histogram of age distribution of prevalent IBD cases with stacked 
proportions (expressed as percentage of total cases) according to IBD phenotype. 
IBD= inflammatory bowel disease. CD= Crohn’s disease. UC= ulcerative colitis. IBDU= 
inflammatory bowel disease-unclassified. 
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Figure 2: histogram of age distribution of incident IBD cases with stacked proportions 
(expressed as percentage of total cases) according to IBD phenotype. 
IBD= inflammatory bowel disease. CD= Crohn’s disease. UC= ulcerative colitis. IBDU= 
inflammatory bowel disease-unclassified. 
 
 
 
 
This article is protected by copyright. All rights reserved.
